Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 8, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Douglas Tsao Maintained (TBPH) at Strong Buy with Increased Target to $19 on, Nov 8th, 2022
Douglas Tsao of HC Wainwright & Co., Maintained "Theravance Biopharma, Inc." (TBPH) at Strong Buy with Increased Target from $12 to $19 on, Nov 8th, 2022.
Douglas has made no other calls on TBPH in the last 4 months.
There is 1 other peer that has a rating on TBPH. Out of the 1 peers that are also analyzing TBPH, 0 agree with Douglas's Rating of Hold.
This is the rating of the analyst that currently disagrees with Douglas
- Vikram Purohit of "Morgan Stanley" Maintained at Sell with Decreased Target to $10 on, Monday, July 25th, 2022
